Brokers Issue Forecasts for 908 Devices Q1 Earnings

908 Devices Inc. (NASDAQ:MASS - Free Report) - William Blair issued their Q1 2026 earnings estimates for shares of 908 Devices in a research note issued on Tuesday, January 14th. William Blair analyst M. Larew anticipates that the company will earn ($0.37) per share for the quarter. The consensus estimate for 908 Devices' current full-year earnings is ($1.99) per share. William Blair also issued estimates for 908 Devices' Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.28) EPS and Q4 2026 earnings at ($0.24) EPS.

MASS has been the topic of a number of other research reports. Leerink Partners reiterated a "market perform" rating and issued a $4.00 price target (down previously from $12.00) on shares of 908 Devices in a report on Wednesday, November 13th. Stifel Nicolaus reduced their target price on 908 Devices from $17.00 to $6.00 and set a "buy" rating on the stock in a report on Wednesday, November 13th. Leerink Partnrs lowered 908 Devices from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, November 13th. Finally, Stephens reaffirmed an "overweight" rating and issued a $6.00 price objective on shares of 908 Devices in a research note on Wednesday.

908 Devices Stock Performance

908 Devices stock traded up $0.04 during trading on Thursday, reaching $2.95. The company had a trading volume of 1,776,552 shares, compared to its average volume of 1,707,348. 908 Devices has a 12-month low of $1.81 and a 12-month high of $8.50. The stock's 50 day moving average price is $2.39 and its two-hundred day moving average price is $3.53. The firm has a market capitalization of $102.86 million, a price-to-earnings ratio of -1.67 and a beta of 0.96.

Institutional Trading of 908 Devices

Several large investors have recently added to or reduced their stakes in MASS. Charles Schwab Investment Management Inc. boosted its position in shares of 908 Devices by 14.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 220,477 shares of the company's stock worth $765,000 after buying an additional 28,015 shares during the period. Geode Capital Management LLC boosted its holdings in 908 Devices by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 567,788 shares of the company's stock worth $1,970,000 after acquiring an additional 6,634 shares during the period. Millennium Management LLC grew its position in 908 Devices by 35.5% in the second quarter. Millennium Management LLC now owns 618,310 shares of the company's stock valued at $3,184,000 after acquiring an additional 161,922 shares in the last quarter. State Street Corp grew its position in 908 Devices by 1.2% in the third quarter. State Street Corp now owns 479,044 shares of the company's stock valued at $1,662,000 after acquiring an additional 5,704 shares in the last quarter. Finally, Barclays PLC raised its stake in shares of 908 Devices by 452.7% during the third quarter. Barclays PLC now owns 46,214 shares of the company's stock valued at $160,000 after purchasing an additional 37,853 shares during the period. 88.06% of the stock is currently owned by institutional investors and hedge funds.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.